STAT November 6, 2025
Biohaven and Uniqure fault agency volatility for setbacks. The reality may be more complicated
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced...
Today's Sponsors
Today's Sponsor